CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News UpdateEUROPE: EU Expands Use of Roche's Pegasys in Chronic Hepatitis C
March 19, 2013
On March 18, the pharmaceutical company Roche announced that the European Medicines Agency had expanded approval of its drug Pegasys plus ribavirin for treatment of chronic hepatitis C virus (HCV) infection to include children five years of age and older who have not received treatment and who have tested positive for HCV. According to the drug company, mother-to-child HCV transmission is the most common mode of infection for children, with approximately 65,000 youth now estimated to be living with chronic HCV in Europe. Roche says Pegasys in combination with ribavirin is currently the foundation treatment for chronic HCV in adults.